Cancer Vaccine by Fusions of Dendritic and Cancer Cells
Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells repr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2009/657369 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556162730426368 |
|---|---|
| author | Shigeo Koido Eiichi Hara Sadamu Homma Yoshihisa Namiki Toshifumi Ohkusa Jianlin Gong Hisao Tajiri |
| author_facet | Shigeo Koido Eiichi Hara Sadamu Homma Yoshihisa Namiki Toshifumi Ohkusa Jianlin Gong Hisao Tajiri |
| author_sort | Shigeo Koido |
| collection | DOAJ |
| description | Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination. |
| format | Article |
| id | doaj-art-d2b632d6135a4f328ef06904b3e95aa1 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-d2b632d6135a4f328ef06904b3e95aa12025-02-03T05:46:15ZengWileyClinical and Developmental Immunology1740-25221740-25302009-01-01200910.1155/2009/657369657369Cancer Vaccine by Fusions of Dendritic and Cancer CellsShigeo Koido0Eiichi Hara1Sadamu Homma2Yoshihisa Namiki3Toshifumi Ohkusa4Jianlin Gong5Hisao Tajiri6Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanSaitama Cancer Center Research Institute for Clinical Oncology, Saitama 277-8567, JapanDepartment of Oncology, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanInstitute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo 277-8567, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanDepartment of Medicine, Boston University School of Medicine, Boston, MA 02118, USADivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 277-8567, JapanDendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination.http://dx.doi.org/10.1155/2009/657369 |
| spellingShingle | Shigeo Koido Eiichi Hara Sadamu Homma Yoshihisa Namiki Toshifumi Ohkusa Jianlin Gong Hisao Tajiri Cancer Vaccine by Fusions of Dendritic and Cancer Cells Clinical and Developmental Immunology |
| title | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
| title_full | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
| title_fullStr | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
| title_full_unstemmed | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
| title_short | Cancer Vaccine by Fusions of Dendritic and Cancer Cells |
| title_sort | cancer vaccine by fusions of dendritic and cancer cells |
| url | http://dx.doi.org/10.1155/2009/657369 |
| work_keys_str_mv | AT shigeokoido cancervaccinebyfusionsofdendriticandcancercells AT eiichihara cancervaccinebyfusionsofdendriticandcancercells AT sadamuhomma cancervaccinebyfusionsofdendriticandcancercells AT yoshihisanamiki cancervaccinebyfusionsofdendriticandcancercells AT toshifumiohkusa cancervaccinebyfusionsofdendriticandcancercells AT jianlingong cancervaccinebyfusionsofdendriticandcancercells AT hisaotajiri cancervaccinebyfusionsofdendriticandcancercells |